drugset / Trial / NCT02336386
CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary Plasmacytoma
Phase 3
Unknown
100 enrolled
Beijing Chao Yang Hospital
Peking University People's Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether Cyclophosphamide, Liposome doxorubicin and Dexamethasone（CDD) Plus Bortezomib might have effective in extramedullary plasmacytoma.
Timeline
- Start
- 2014-12
- Primary completion
- 2016-12
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | Subcutaneous |
| Background | Cyclophosphamide | Other / unclassified | 300 mg/m2 | — |
| Background | Dexamethasone | Small molecule | 20 mg | Oral |
| Background | Doxorubicin | Other / unclassified | 40 mg | — |